Search results for "TOP"

showing 10 items of 17685 documents

SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of m…

2018

Background Chronic myelogenous leukemia (CML) is a myeloproliferative disorder caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, resulting from the t(9;22) chromosomal translocation. Imatinib (gleevec, STI-571) is a selective inhibitor of BCR-ABL activity highly effective in the treatment of CML. However, even though almost all CML patients respond to treatment with imatinib or third generation inhibitors, these drugs are not curative and need to be taken indefinitely or until patients become resistant. Therefore, to get a definitive eradication of leukemic cells, it is necessary to find novel therapeutic combinations, for achieving greater efficacy and fewer side effec…

0301 basic medicineProteomicsCancer ResearchCurcuminCML cellsCellReceptors Cytoplasmic and NuclearKaryopherinsTransfectionlcsh:RC254-282Mass SpectrometrymiR-22/IPO7/HIF-1α axis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemiR-22/IPO7/HIF-1α axiSettore BIO/13 - Biologia Applicatahemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansCML cells; Curcumin; miR-22/IPO7/HIF-1α axis; SWATH-MS; Oncology; Cancer ResearchOncogeneChemistryResearchCML cellImatinibTransfectionmedicine.diseaseHypoxia-Inducible Factor 1 alpha Subunitlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchCurcuminSWATH-MSK562 CellsTyrosine kinaseK562 cellsChronic myelogenous leukemiamedicine.drug
researchProduct

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.

2018

Abstract To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I immunoprecipitation followed by elution of MHC class I-loaded peptides in breast cancer cells. We determined the sequence of 3196 MHC class I ligands representing 1921 proteins from a panel of 20 breast cancer cell lines. After removing duplicate peptides, i.e., the same peptide eluted from more than one cell line, the total number of unique peptides was 2740. Of the unique peptides eluted, more than 1750 had been previously identified, and of these, sixteen have been shown to be immunogenic. Importantly, half of these immunogenic peptides were shared between different breast cancer…

0301 basic medicineProteomicsPlant BiologyPeptideLigandsBiochemistryEpitopeAnalytical ChemistryEpitopesBreast cancerT cell-mediated immune responseHLA Antigens2.1 Biological and endogenous factorsAetiologyCancerchemistry.chemical_classificationAntigen PresentationTumorbiologyBiochemistry & Molecular BiologyBiophysicsBreast NeoplasmsArticleCell LineVaccine Related03 medical and health sciencesImmune systemBreast cancerAntigenAntigens NeoplasmCell Line TumorMHC class ImedicineGeneticsHumansAmino Acid SequenceAntigensMHC class I-restricted peptidesTumor associated antigensPreventionHistocompatibility Antigens Class ICancermedicine.diseaseHigh-Throughput Screening Assays030104 developmental biologychemistryCell cultureNeo-antigensMutationbiology.proteinCancer researchNeoplasmImmunizationBiochemistry and Cell Biology
researchProduct

Proteomics Standards Initiative: Fifteen Years of Progress and Future Work.

2017

Abstract: The Proteomics Standards Initiative (PSI) of the Human Proteome Organization (HUPO) has now been developing and promoting open community standards and software tools in the field of proteomics for 15 years. Under the guidance of the chair, co-chairs, and other leadership positions, the PSI working groups are tasked with the development and maintenance of community standards via special workshops and ongoing work. Among the existing, ratified standards, the PSI working groups continue to update PSI-MI XML, MITAB, mzML, mzIdentML, mzQuantML, mzTab, and the MIAPE (Minimum Information About a Proteomics Experiment) guidelines with the advance of new technologies and techniques. Furthe…

0301 basic medicineProteomicsprotein quantificationEmerging technologiesComputer sciencecomputer.internet_protocolGuidelines as Topiccomputer.software_genreBiochemistry03 medical and health sciencesprotein identificationHuman proteome projectHumansCommunity standardsquality controlDatabases ProteinBiologydatabasemass spectrometryComputer. Automation030102 biochemistry & molecular biologyApplication programming interfaceProteomics Standards InitiativeGeneral ChemistryReference StandardsData sciencemetabolomicsChemistry030104 developmental biologyPerspectivedata standardWeb servicebioinformatics softwareWorking groupcomputerXMLSoftwaremolecular interactionsJournal of proteome research
researchProduct

Asthmatics with high levels of serum surfactant protein D have more severe disease.

2016

Pulmonary surfactant is a mixture of lipids and surfactant-specific proteins that covers the alveolar surface, as well as the terminal conducting airways, lowering the surface tension at the air–liquid interface during breathing. The involvement of pulmonary surfactant in the pathophysiology of asthma has been suggested. An interesting working hypothesis is that the surface tension of the peripheral airways is altered in asthma, because the inflammatory process affects the structure and function of surfactant, leading to excessive airway narrowing and features of air trapping. We explored whether serum levels of surfactant protein D (SP-D) in asthmatics are related to the severity of the di…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalesurfactantStatistics as TopicSevere diseasemacromolecular substancesSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineSeverity of illnessMedicineHumansAnti-Asthmatic Agentsbusiness.industrySmall airwaysSurfactant protein DReproducibility of Resultsrespiratory systemMiddle AgedPulmonary Surfactant-Associated Protein DAsthmaRespiratory Function Tests030104 developmental biology030228 respiratory systemImmunologyBiomarker (medicine)FemalebusinessBiomarkersThe European respiratory journal
researchProduct

Evidence in immunotherapy for paediatric respiratory allergy: Advances and recommendations. Document of the Immunotherapy Working Group of the Spanis…

2016

Allergic respiratory diseases are major health problems in paediatric population due their high level of prevalence and chronicity, and to their relevance in the costs and quality of life. One of the most important risk factors for the development of airway diseases in children and adolescents is atopy. The mainstays for the treatment of these diseases are avoiding allergens, controlling symptoms, and preventing them through sustained desensitization by allergen immunotherapy (AIT). AIT is a treatment option that consists in the administration of increasing amounts of allergens to modify the biological response to them, inducing long-term tolerance even after treatment has ended. This treat…

0301 basic medicinePulmonary and Respiratory MedicineAllergen immunotherapymedicine.medical_specialtyAllergybusiness.industrymedicine.medical_treatmentImmunologyRespiratory allergyGeneral MedicineImmunotherapyDiseasemedicine.diseaseAtopy03 medical and health sciences030104 developmental biology0302 clinical medicineQuality of life (healthcare)030228 respiratory systemImmunologyImmunology and AllergyMedicinebusinessIntensive care medicineDesensitization (medicine)Allergologia et Immunopathologia
researchProduct

The microbiome in respiratory medicine: current challenges and future perspectives

2017

The healthy lung has previously been considered to be a sterile organ because standard microbiological culture techniques consistently yield negative results. However, culture-independent techniques report that large numbers of microorganisms coexist in the lung. There are many unknown aspects in the field, but available reports show that the lower respiratory tract microbiota: 1) is similar in healthy subjects to the oropharyngeal microbiota and dominated by members of the Firmicutes, Bacteroidetes and Proteobacteria phyla; 2) shows changes in smokers and well-defined differences in chronic respiratory diseases, although the temporal and spatial kinetics of these changes are only partially…

0301 basic medicinePulmonary and Respiratory MedicineCystic FibrosisRespiratory SystemDiseaseBiologyCystic fibrosisMicePulmonary Disease Chronic Obstructive03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineRisk FactorsTerminology as TopicProteobacteriaPulmonary MedicinemedicineAnimalsHumansIdiopathic Interstitial PneumoniasMicrobiomeLung11 Medical and Health SciencesBronchiectasisLungBacteroidetesMicrobiotamedicine.diseasebiology.organism_classificationBronchiectasis030104 developmental biologymedicine.anatomical_structure030228 respiratory systemHost-Pathogen InteractionsImmunologyDysbiosisProteobacteriaDysbiosisEuropean Respiratory Journal
researchProduct

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized…

2019

Objectives: Concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), The aim of this study was to assess the safety and efficacy of oral vinorelbine and cisplatin (OVP) compared with etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting. Material and methods: An open-label, randomized phase II trial was undertaken including 23 hospitals in Spain. Adults with untreated unresectable stage III NSCLC were randomizedl:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1-5 and 29-32 with cisplatin on d…

0301 basic medicinePulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDisease-free survivalmedicine.medical_treatmentNeoplasm metastasisAdministration OralVinorelbine03 medical and health sciences0302 clinical medicineNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalneoplasmsEtoposideAgedNeoplasm StagingEtoposideCisplatinbusiness.industryStandard treatmentVinorelbineChemoradiotherapyMiddle AgedPhase IIrespiratory tract diseasesRadiation therapySurvival RateClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantFemalePatient SafetyCisplatinbusinessClinical trial Disease-free survival Etoposide Neoplasm metastasis Non-small cell lung cancer Phase II Vinorelbinemedicine.drug
researchProduct

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

2019

Hepatopulmonary syndrome (HPS) is a pulmonary vascular complication of liver disease that affects up to 30% of patients with cirrhosis [1]. Intrapulmonary vascular dilatations and shunts result in gas exchange abnormalities, ranging from elevated alveolar-arterial oxygen gradients with no hypoxemia to very severe hypoxemia [1, 2]. Currently, liver transplantation (LT) is the only treatment option [3]. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing liver disease severity that has been validated to predict the 3-months waitlist mortality, and is used by Eurotransplant for prioritising allocation of liver transplants [4]. Footnotes This manuscript has recently b…

0301 basic medicinePulmonary and Respiratory MedicineRiskScoring systemmedicine.medical_treatmentMedizinVascular complicationLiver transplantationEnd Stage Liver Disease03 medical and health sciences0302 clinical medicineSevere hypoxemiaNothingMedicineHumansRegistriesProportional Hazards ModelsRetrospective Studiesbusiness.industryConflict of interestTreatment optionsLiver TransplantationEuropeOxygen030104 developmental biologyTreatment OutcomeLaw030211 gastroenterology & hepatologybusinessProduction teamHepatopulmonary SyndromeThe European respiratory journal
researchProduct

Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases

2019

The pathogenetic role of angiogenesis in interstitial lung diseases (ILDs) is controversial. This study represents the first investigation of the spatial complexity and molecular motifs of microvascular architecture in important subsets of human ILD. The aim of our study was to identify specific variants of neoangiogenesis in three common pulmonary injury patterns in human ILD.We performed comprehensive and compartment-specific analysis of 24 human lung explants with usual intersitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) and alveolar fibroelastosis (AFE) using histopathology, microvascular corrosion casting, micro-comupted tomography based volumetry and gene expression…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyAngiogenesisVascular remodelling in the embryoNeovascularization03 medical and health sciences0302 clinical medicineVascularitymedicineHumansIdiopathic Interstitial PneumoniasLungIdiopathic interstitial pneumoniaLungNeovascularization Pathologicbusiness.industryrespiratory systemmedicine.diseaserespiratory tract diseases3. Good healthPneumonia030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisHistopathologymedicine.symptomLung Diseases InterstitialTomography X-Ray ComputedbusinessEuropean Respiratory Journal
researchProduct

Cytotoxic activity of the histone deacetylase 3-Selective inhibitor Pojamide on MDA-MB-231 triple-negative breast cancer cells

2019

We examined the effects of the ferrocene-based histone deacetylase-3 inhibitor Pojamide (N1-(2-aminophenyl)-N8-ferrocenyloctanediamide) and its two derivatives N1-(2-aminophenyl)-N6-ferrocenyladipamide and N1-(2-aminophenyl)-N8-ferroceniumoctanediamide tetrafluoroborate on triple-negative MDA-MB-231 breast cancer cells. Viability/growth assays indicated that only the first two compounds at 70 &mu

0301 basic medicineQD0901Triple Negative Breast Neoplasmslcsh:Chemistry0302 clinical medicinebreast cancer cellmitochondrial transmembrane potentialCytotoxic T cellQDSettore BIO/06 - Anatomia Comparata E Citologialcsh:QH301-705.5SpectroscopyTriple-negative breast cancerreactive oxygen speciesCell DeathChemistryHistone deacetylase inhibitorQapoptosisGeneral MedicineCell cycle3. Good healthComputer Science Applications030220 oncology & carcinogenesisFemalecell cycleProgrammed cell deathautophagymedicine.drug_classCell SurvivalCatalysisArticleHistone DeacetylasesInorganic Chemistry03 medical and health sciencesCell Line TumormedicineBiomarkers TumorHumansViability assayPhysical and Theoretical ChemistryMolecular Biologyhistone deacetylase inhibitorcell viabilityOrganic ChemistryAutophagyapoptosiMatrix MetalloproteinasesHistone Deacetylase InhibitorsSettore BIO/18 - Genetica030104 developmental biologylcsh:Biology (General)lcsh:QD1-999ApoptosisCancer researchQD0146breast cancer cells
researchProduct